Compare Li Auto Inc (LI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs TG Therapeutics Inc — how do they compare? Li Auto Inc trades at $12.68 (market cap $12.28B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Li Auto Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| LI | TGTX | |
|---|---|---|
Market Cap | $12.28B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.69 | $59.06 |
52-Week Low | $11.74 | $26.94 |
Enterprise Value | $1.11B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $12.49, down 2.73% on the day, amid a bearish technical signal and mixed earnings performance. The company reported a net income margin of -1.66% for 2025, with revenue declining to $112.31 billion from $144.5 billion in 2024, while launching new SUV models like the Li L6 in July 2026 to boost deliveries. Analyst consensus is a 'Buy' with a $14.80 price target, but negative cash flow and competitive pressures in China's EV market pose challenges.
Outlook remains cautious due to profitability concerns and volatile cash flows, with near-term risks from domestic competition and global expansion hurdles. The stock offers potential upside if execution improves, but investors should monitor delivery trends and margin recovery amid industry headwinds.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
